AAP
CDIO icon

Arax Advisory Partners’s Cardio Diagnostics CDIO Stock Holding History

Arax Advisory Partners’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$17 – 3876
2025
Q4 		$17 Hold
6
– – ﹤0.01% 4030
2025
Q3 		$25 Hold
6
– – ﹤0.01% 3566
2025
Q2 		$22 Buy
+6
New +$45 ﹤0.01% 3012

Other funds holding CDIO

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Arax Advisory Partners's CDIO Position: Q1 2026 in Review

Arax Advisory Partners sold out of Cardio Diagnostics (CDIO) in Q1 2026, closing a stake of 6 shares — an estimated $17 sold.

Arax Advisory Partners first reported a position in CDIO in Q2 2025 and held it in 3 quarters. The position peaked at $25 in Q3 2025. 16 funds tracked by Wall St. Rank hold CDIO as of Q1 2026.

  • Arax Advisory Partners reported no remaining Cardio Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 6 Cardio Diagnostics shares in Q1 2026, an estimated $17.
  • Arax Advisory Partners first reported a position in Cardio Diagnostics in Q2 2025 and held it in 3 quarters.
  • Arax Advisory Partners's Cardio Diagnostics position peaked at $25 in Q3 2025.
  • 16 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.